Priyanka Chopra Jonas and Crocs to Donate 50,000 Pairs of Classic Clogs to UNICEF
12.12.2019 16:00:00 EET | Business Wire | Press release
Crocs, Inc. (NASDAQ: CROX), in partnership with UNICEF Goodwill Ambassador Priyanka Chopra Jonas, today announced that 50,000 pairs of Crocs Classic clogs will be donated over the next year to underserved school children in Belize through UNICEF. This charitable contribution supports the actor’s joint mission to help children around the world and provide them with more opportunities to achieve an education.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005213/en/
In partnership with UNICEF Goodwill Ambassador and Crocs Global Brand Ambassador Priyanka Chopra Jonas, Crocs recently donated 25,000 pairs of Classic Clogs to underserved school children in Belize through UNICEF. This is the first of two donations to be made to this region through this partnership. A total of 50,000 pairs will ultimately be donated over the next year. (Photo: Business Wire)
Recently, Crocs announced award-winning actor, activist, and entrepreneur Priyanka Chopra Jonas would serve as a global brand ambassador for its 2020 “Come As You Are” marketing campaign. A special element of the partnership is this collaboration to jointly support UNICEF.
“At Crocs, we believe being comfortable in your own shoes is a first step to accessing quality education,” said Heidi Cooley, Vice President of Global Marketing, Crocs. “With this donation, we hope to deliver shoes to more than half of the student population attending primary and secondary school classes in Belize, while reducing the financial burden for their families.”
“As a global ambassador for UNICEF, I’m dedicated to connecting organizations that together can have a large and positive impact on children around the world,” said Priyanka Chopra Jonas. “Working with Crocs to distribute more than 50,000 pairs of their Classic Clogs will have a tremendous impact on school-age children in Belize, reducing barriers to education, and easing social and peer-related stressors that come with not having basic everyday resources that many take for granted.”
Barriers to education in Belize include poverty, disability, late entry, and inadequate preparation for primary school, among other factors. In November, members of UNICEF USA and Crocs visited Belize, where they distributed an initial 25,000 pairs of Crocs – the first of two parts of this donation – to students. A video documenting that journey and showing first-hand the positive impact of the contribution can be found linked here.
“UNICEF USA is grateful for Crocs’ generous shoe donation to help remove one of the barriers that can hinder school attendance in Belize, especially during early childhood education,” said Gabriella Morris, Senior Vice President of Strategic Partnerships, UNICEF USA. “Education is essential for children to live to their fullest potential, and together, we can help give each child the opportunity for quality education.”
About Crocs, Inc.
Crocs, Inc. (NASDAQ: CROX) is a world leader in innovative casual footwear for women, men, and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram, and Twitter.
About UNICEF
The United Nations Children's Fund (UNICEF) works in more than 190 countries and territories to put children first. UNICEF has helped save more children’s lives than any other humanitarian organization, by providing health care and immunizations, clean water and sanitation, nutrition, education, emergency relief, and more. UNICEF USA supports UNICEF's work through fundraising, advocacy, and education in the United States. Together, we are working toward the day when no children die from preventable causes and every child has a safe and healthy childhood. For more information, visit www.unicefusa.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005213/en/
Contact information
Media Contacts:
Crocs
Melissa Layton
mlayton@crocs.com
UNICEF
Ann Reinking Whitener
areinking@unicefusa.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
